Cardiac Biomarkers Market is growing at a CAGR of 10.5 % in the forecast period (2024-2031)
Cardiac biomarkers are measurable biological substances—such as troponins, natriuretic peptides, and creatine kinase-MB—that indicate heart function and are critical for diagnosing cardiovascular events like myocardial infarction and heart failure. The global cardiac biomarkers market is expanding rapidly, driven by the increasing prevalence of cardiovascular diseases, advancements in diagnostic technologies, and rising awareness about early detection and personalized treatment. Innovations in testing methodologies have improved the sensitivity and specificity of these biomarkers, leading to enhanced diagnostic accuracy in both hospital and point-of-care settings. Additionally, ongoing investments in healthcare infrastructure and supportive government initiatives in emerging economies are further propelling market growth, positioning the cardiac biomarkers market for significant expansion in the coming years.
Download Free Sample PDF: https://www.datamintelligence.com/download-sample/cardiac-biomarkers-market
Market Growth Drivers:
The global cardiac biomarkers market is being propelled by a surge in cardiovascular disease cases, an expanding geriatric population, and ongoing market developments. As more people face heart-related issues, the need for effective diagnostic tools increases, driving market growth. These factors underscore the critical role that cardiac biomarkers play in early detection and treatment, positioning them as essential components in modern cardiovascular care.
Data from reputable sources further highlight the market’s potential. For instance, the British Heart Foundation reported that cardiovascular diseases claimed over 168,319 lives in 2020. Additionally, the World Health Organization noted that more than 1 billion people were aged 60 and above in 2020—a figure expected to reach 2.1 billion by 2050. Moreover, with approximately 8 million global deaths attributed to tobacco consumption annually, the burden of heart disease continues to grow, reinforcing the demand for advanced diagnostic solutions.
However, the market faces significant challenges due to the lack of specificity in current cardiac biomarker tests and the need for more sensitive analysis systems. The American Association for Clinical Chemistry (AACC) has emphasized that point-of-care testing (POCT) for biomarkers like troponin requires high-sensitivity diagnostic tools to detect low biomarker levels rapidly. Since it can take several hours for troponin levels to rise to detectable levels, the current diagnostic methods may not suffice in emergency scenarios, thus hindering market growth.
Market Segments:
By Cardiac Biomarker Tests: Troponin, Creatine kinase, Myoglobin, Galectin-3, Other Biomarker Tests.
By Application: Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, Angina, others.
By Testing Location: Laboratory Testing, Point of Care Testing.
Competitive Landscape
- Thermo Fisher Scientific
- Abbott Laboratories
- Beckman Coulter
- Roche Diagnostics Corporation
- Becton Dickinson And Co.
- Bio-Rad Laboratories
- BioMerieux
- Siemens Healthcare
- LumiraDx
- Randox Laboratories
Customize Your Scope: https://www.datamintelligence.com/customize/cardiac-biomarkers-market
Regional Growth
North America is set to command the global cardiac biomarkers market, maintaining a significant market share throughout the forecast period (2023-2030). This leadership is driven by the region’s high incidence of cardiovascular diseases; for instance, the CDC reported that in 2020, a person in the U.S. died from cardiovascular disease every 34 seconds, resulting in over 697,000 fatalities. Such alarming statistics underscore the urgent need for effective diagnostic solutions, fueling demand for cardiac biomarkers.
The region’s dominance is further reinforced by the presence of major industry players, including Abbott Laboratories, Beckman Coulter, Roche Diagnostics Corporation, Becton Dickinson, Bio-Rad Laboratories, and Thermo Fisher Scientific. These companies, predominantly based in the United States, employ diverse market strategies that help capture a large share of the global cardiac biomarkers market. Their extensive research and innovation efforts continuously drive market expansion and technological advancements.
Key Development:
For example, in April 2021, Roche introduced a suite of five new applications for two critical cardiac biomarkers—high-sensitive cardiac troponin T (cTnT-hs) and N-terminal pro-brain natriuretic peptide (NT-proBNP)—using its advanced Elecsys technology. Additionally, in July 2021, Beckman Coulter signed a definitive agreement with Quidel Corporation to secure all rights for manufacturing, distributing, and selling a BNP assay for its analyzers. These strategic initiatives highlight how key players are shaping the market and solidifying North America’s leadership in the global cardiac biomarkers arena.
For Detailed Report: https://www.datamintelligence.com/enquiry/cardiac-biomarkers-market
